By contrast, patients with CM were characterized by exhausted CD8+ T cells that expressed high level of LAG3 and CTLA4. This implied that the combination of LAG3 and CTLA4 inhibitors might be more appropriate for CM patients. The gene discussed is CTLA4; the disease is cutaneous mastocytosis.